Aim: To develop a bioanalytical method to support pharmacokinetic evaluation of DNDI-VL-2098 in mouse, rat, dog and hamster following oral administration. Results & methodology: A robust LC–MS/MS bioanalytical method was developed to quantify DNDI-VL-2098. DNDI-VL-2098 showed time-dependent recovery loss in acetonitrile precipitated plasma in all species. Acid-lysed whole blood was identified as a matrix in which recovery was stable over time. A two-step extraction procedure was used, with protein precipitation followed by liquid–liquid extraction with methyl tert-butyl ether. The assay was validated in the dynamic range of 5–5000 ng/ml for mouse, rat and dog blood, and a fit-for-purpose method was developed for hamster. Conclusion: A specific LC–MS/MS assay for DNDI-VL-2098 was developed and validated in hemolyzed blood.
Keywords:
- albumin-mediated metabolism
- hemolyzed blood
- LC–MS/MS
- nitroimidazo-oxazole
- plasma instability
- two-step sample preparation
- visceral leishmaniasis